Table 2

Use of HT and risk of colorectal cancer

HT usePYCRC casesRR (95% CI)
StatusNon-use2126 7533020Reference
Current use320 2024410.88 (0.80 to 0.98)
Past use203 7593380.98 (0.87 to 1.09)
Ever use523 9617790.92 (0.85 to 1.00)
HT typeNon-use2126 7533020Reference
ET*159 4952520.91 (0.80 to 1.04)
ET (oestradiol)* 118 910 159 0.87 (0.74 to 1.03)
ET (oestriol)* 40 585 93 0.98 (0.79 to 1.21)
Tibolone*20 043210.86 (0.56 to 1.32)
EPT*91 6541060.85 (0.70 to 1.03)
Other*49 010620.86 (0.67 to 1.10)
RouteNon-use2126 7533020Reference
ET oral*57 031940.83 (0.68 to 1.03)
ET vaginal*89 7191340.92 (0.77 to 1.09)
ET transdermal*7246151.63 (0.98 to 2.71)
EPT oral*90 1261060.86 (0.71 to 1.05)
EPT transdermal*11630
Other74 917920.86 (0.70 to 1.06)
Oral doseOestrogen 1 mg/day*0.87 (0.73 to 1.04)
Unit increaseProgestin 10 mg/month*1.01 (0.86 to 1.19)
  • Incidence RRs were adjusted for age, number of births, highest level of education, marital status, use of antihypertensives, antidiabetics, statins and thyroid therapy.

  • *Current use.

  • CRC, colorectal cancer; EPT, combined oestrogen–progestin therapy; ET, oestrogen therapy. The italic font denotes subtypes of ET; HT, hormonal therapy; PY, person-years; RR, rate ratio.